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METHODOLOGY ARTICLE
A protocol for custom CRISPR Cas9 
donor vector construction to truncate genes 
in mammalian cells using pcDNA3 backbone
Neftali Vazquez1†, Lilia Sanchez1†, Rebecca Marks1†, Eduardo Martinez1, Victor Fanniel1, Alma Lopez1, 
Andrea Salinas1, Itzel Flores1, Jesse Hirschmann1, Robert Gilkerson1, Erin Schuenzel1, Robert Dearth1, 
Reginald Halaby2, Wendy Innis‑Whitehouse3 and Megan Keniry1* 
Abstract 
Background: Clustered regularly interspaced short palindromic repeat (CRISPR) RNA‑guided adaptive immune 
systems are found in prokaryotes to defend cells from foreign DNA. CRISPR Cas9 systems have been modified and 
employed as genome editing tools in wide ranging organisms. Here, we provide a detailed protocol to truncate genes 
in mammalian cells using CRISPR Cas9 editing. We describe custom donor vector construction using Gibson assembly 
with the commonly utilized pcDNA3 vector as the backbone.
Results: We describe a step‑by‑step method to truncate genes of interest in mammalian cell lines using custom‑
made donor vectors. Our method employs 2 guide RNAs, mutant Cas9D10A nickase (Cas9 = CRISPR associated 
sequence 9), and a custom‑made donor vector for homologous recombination to precisely truncate a gene of 
interest with a selectable neomycin resistance cassette (NPTII: Neomycin Phosphotransferase II). We provide a detailed 
protocol on how to design and construct a custom donor vector using Gibson assembly (and the commonly utilized 
pcDNA3 vector as the backbone) allowing researchers to obtain specific gene modifications of interest (gene trunca‑
tion, gene deletion, epitope tagging or knock‑in mutation). Selection of mutants in mammalian cell lines with G418 
(Geneticin) combined with several screening methods: western blot analysis, polymerase chain reaction, and Sanger 
sequencing resulted in streamlined mutant isolation. Proof of principle experiments were done in several mammalian 
cell lines.
Conclusions: Here we describe a detailed protocol to employ CRISPR Cas9 genome editing to truncate genes of 
interest using the commonly employed expression vector pcDNA3 as the backbone for the donor vector. Provid‑
ing a detailed protocol for custom donor vector design and construction will enable researchers to develop unique 
genome editing tools. To date, detailed protocols for CRISPR Cas9 custom donor vector construction are limited (Lee 
et al. in Sci Rep 5:8572, 2015; Ma et al. in Sci Rep 4:4489, 2014). Custom donor vectors are commercially available, 
but can be expensive. Our goal is to share this protocol to aid researchers in performing genetic investigations that 
require custom donor vectors for specialized applications (specific gene truncations, knock‑in mutations, and epitope 
tagging applications).
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Background
A significant proportion of bacteria and archaea (roughly 
40 and 90% respectively) employ [1, 2] CRISPR Cas9 
mechanisms as an adaptive immunological response 
against virus and plasmid foreign DNA [3–10]. Research-
ers have exploited the CRISPR Cas9 molecular machinery 
to target genes in numerous organisms such as yeast, flies, 
worms, and mammals leading to groundbreaking discover-
ies [11–14]. Although other approaches have been utilized 
for genome editing for decades, CRISPR Cas9 technology 
has reshaped genetic engineering by providing a quick and 
facile tool, greatly accelerating research [13, 14].
Endogenous CRISPR Cas9 (and related) systems serve 
as an acquired immunological response [3–5, 15–18]. 
Invading DNA (from plasmids and viruses) becomes 
incorporated into the CRISPR locus of the prokary-
otic genome. CRISPR loci typically have noncontiguous 
direct repeats and spacers that contain the invading DNA 
sequences [19]. Transcription of the CRISPR locus pro-
duces a pre-crRNA (crRNA = CRISPR RNA) that base 
pairs with a trans-activating-crRNA (tracrRNA, also 
encoded by CRISPR system), leading to processing and 
incorporation into a Cas9-containing complex [20–22]. 
Many prokaryotes harbor specific endonucleases such as 
Cas9 that contain two domains: RuvC-like [an endonu-
clease domain named for an Escherichia coli (E. Coli) pro-
tein involved in DNA repair] and HNH (an endonuclease 
domain named for characteristic histidine and asparagine 
residues) to cleave foreign DNA [15]. Hybridized crRNA/
tracrRNA serves as a guide for Cas9 to cleave foreign 
DNA in a sequence-specific manner. With heterologous 
CRISPR Cas9 systems such as those utilized in human 
cells, a chimeric guide RNA (gRNA) is employed to tar-
get specific sequences [23]. The gRNA contains a fusion 
between tracrRNA and crRNA that enables specific tar-
geting of Cas9 to a gene of interest [24].
Employing CRISPR Cas9 technology as a gene editing 
tool is a recent development in the field of molecular biol-
ogy [14, 24]. This tool has already had a transformative 
impact on research, allowing for the quick identification 
of mutations in wide-ranging experimental settings [23]. 
However, it has become increasingly evident that utili-
zation of CRISPR Cas9 can lead to off-target effects [19, 
25, 26]. CRISPR Cas9 can tolerate base pair mismatches 
between the gRNA and target sequences [25, 27, 28]. 
CRISPR technology utilizes the host DNA repair machin-
ery to resolve DNA lesions, leading to the isolation of 
mutations [29]. One issue that we encountered when try-
ing to mutate genes in cancer cell lines, widely reported 
by others, was that mutation frequencies vary widely 
depending on the methodology employed, the locus being 
mutated and screening methods [17, 29]. Chiang et  al. 
observed mutation efficiencies without selection by green 
fluorescent protein (GFP)-based cell sorting of 1–4% in 
HAP1 (near diploid chronic myelogenous leukemia) and 
2–22% in U2OS (human bone osteosarcoma epithelial) 
cell lines [28, 30–32]. In these settings with low muta-
tion frequencies, methods that employ selection (such as 
neomycin resistance) may be necessary to obtain enough 
mutants for study in a cost effective manner. Here, we 
describe a detailed protocol to construct a custom donor 
vector (using the pcDNA3 vector as the backbone) in 
order to truncate the gene of interest. We describe a 
streamlined screening process to isolate and validate 
mutants in settings with low mutation frequencies.
Methods
This protocol can be employed to specifically truncate 
genes of interest using a neomycin resistance cassette 
(NPTII, enabling selection of mutants with G418) in 
mammalian cell lines. Figure  1 shows the basic steps to 
truncate the gene of interest. First, a custom donor vec-
tor needs to be designed and constructed. Next, CRISPR 
Cas9 mutagenesis needs to be performed. Last, mutants 
must be isolated and validated. This protocol addresses 
multiple barriers found with employing CRISPR Cas9 to 
mutate genes. First, we needed to design a custom donor 
vector in order to obtain truncation mutants for our 
research. Although we found many protocols for CRISPR 
mutagenesis, we found a lack of published protocols that 
described custom donor vector construction in detail and 
purchasing a custom donor vector can be expensive [1, 
2]. Secondly, we sought to minimize off-target effects [25, 
Truncang FOXO3 gene using CRISPR 
Build custom donor vector 
using Gibson Assembly 
CRISPR Cas9 mutagenesis in 
mammalian cell lines with 
custom donor vector, 2 guide 
RNAs and Cas9 D10A nickase 
Screen for putave 
mutants and validate 
Fig. 1 Flow chart for CRISPR Cas9 mutagenesis using a custom donor 
vector. A flow chart for CRISPR mutagenesis with custom donor vec‑
tor is depicted
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28, 30–32]. Finally, we wanted to be able to quickly isolate 
mutants for a gene of interest, even if the mutation fre-
quency was low. Many cancer cell lines such as U87MGs 
have deficient homologous recombination repair, making 
CRISPR mutagenesis inefficient [33, 34]. Our approach 
utilized transiently transfected Cas9D10A nickase, two 
gRNAs, and a donor vector to disrupt FOXO3 gene cod-
ing sequence with a neomycin resistance gene. The custom 
donor vector was built using two, separate Gibson assem-
bly cloning steps with the pcDNA3 vector (Figs. 2, 3).  
Construction of FOXO3 donor vector using Gibson 
assembly
Gibson assembly is an extremely efficient method to 
obtain insertions into a plasmid vector of interest [35]. 
The FOXO3 donor vector was prepared using a two-step 
Gibson assembly-based cloning procedure. The com-
plete sequence of the FOXO3 donor vector can be found 
in Additional file  1: Figure S1. Figures  2, 3 depict the 
steps employed to prepare a custom FOXO3 donor vec-
tor. First, a 418 base pair fragment from the FOXO3 gene 
(named FOXO3 Arm 1) was inserted into the pcDNA3 
vector just upstream of the neomycin resistance cassette 
(NPTII), producing an intermediate vector. In the sec-
ond sub-cloning step, (shown in Figs. 2, 3) a 750 base pair 
FOXO3 fragment (Arm 2) was inserted into the donor 
vector.
For optimal results, FOXO3 donor vector sequences 
were selected for (1) proximity to genomic nick sites and 
(2) sufficient sequence length to permit efficient recom-
bination. It is important to note that there are two nick 
sites for FOXO3 in the genome when using 2 gRNAs and 
the Cas9D10A nickase. Therefore, the upstream FOXO3 
fragment (Arm 1) in the donor vector and downstream 
FOXO3 fragment (Arm 2) need to be in regions that are 
in positions amenable to recombination with the two 
genomic CRISPR nick sites. The FOXO3 donor vector 
fragments should be within 20 bases of the nick sites 
Donor Vector Construcon using pcDNA3 
Cut pcDNA3 vector with DraIII and 
purify fragment with spin column 
Amplify PCR fragment with flanking 
pcDNA3 sequences (near DraIII site) 
and purify with spin column 
Perform Gibson Assembly reacon to add first 
donor vector arm (Arm 1 of FOXO3) to pcDNA3 
Isolate sub-clones with FOXO3 Arm 1 and 
confirm by sequencing 
Cut vector with FOXO3 Arm 1 using BstZ17I 
and purify vector using spin column
Amplify PCR fragment with flanking 
pcDNA3 sequences (near BstZ17I site) 
and purify with spin column 
Perform Gibson Assembly reacon to add second 
donor vector arm (Arm 2 of FOXO3) to obtain 
complete FOXO3 donor vector 
Fig. 2 Construction of FOXO3 donor vector. A fragment of FOXO3 (Arm 1) was inserted into the pcDNA3 vector proximal to the DraIII restriction 
site by using Gibson assembly. This intermediate vector was called FOXO3 Arm1 and was utilized to make the final FOXO3 donor vector. Another 
fragment of FOXO3 (Arm 2) was inserted into the FOXO3 Arm1 vector (by Gibson assembly) to obtain the final FOXO3 donor vector. This vector was 
confirmed by Sanger sequencing and employed in CRISPR Cas9 mutagenesis reactions
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and should have at least a few hundred base pairs to pro-
mote recombination between the donor vector and the 
chromosome [26]. In our design, the upstream sequence 
used in the donor vector for FOXO3 Arm 1 contained 
418 chromosomal FOXO3 base pairs; these sequences 
ended seven bases upstream of the gRNA targeting site 
in the genome, allowing for 418 base pairs of homol-
ogy between the donor vector and genome for recom-
bination-mediated repair just before the nick site in the 
genome. The distance between the bottom strand and the 
top strand nick sites made by CRISPR Cas9 D10A was 51 
bases. The donor vector sequences in FOXO3 Arm 1 and 
FOXO3 Arm 2 were non-overlapping. The downstream 
fragment in the donor vector contained 750 bases that 
were homologous to FOXO3 chromosomal DNA (that 
extended beyond the second nick site further down-
stream into the gene) in order to promote recombination; 
the second nick site was 12 bases from the start of the 
FOXO3 Arm 2.
Step‑by‑step Gibson assembly reactions for the 
FOXO3 donor vector
Gibson assembly reactions were performed to insert two 
FOXO3 fragments into the pcDNA3 vector at positions 
that were on either side of neomycin resistance cassette 
(NPTII gene). For the Gibson assembly reaction, there 
needed to be identical sequences on the ends of each piece 
of DNA that would be physically joined. Therefore, the 
ends of each PCR product needed to be identical to the 
piece of pcDNA3 vector to which it would be fused. We 
added pcDNA3 vector sequences to the 5′ ends of PCR 
primers utilized to amplify FOXO3 fragments. Therefore, 
FOXO3 gene fragments (PCR products) had pcDNA3 
sequences on the ends that corresponded to upstream 
and downstream sequences of the utilized restriction sites 
(DraIII for Arm1 and BstZ17I for Arm2) in pcDNA3.
Addition of FOXO3 Arm 1 to donor vector
The pcDNA3 vector was cleaved with DraIII (restric-
tion enzyme from NEB, Ipswich, MA) for 2  h at 37  °C. 
The restriction digest included 1 µg of the pcDNA3 vec-
tor, 4  μL of 10× NEB Cut Smart buffer, 3  μL of DraIII 
restriction enzyme and 27 μL of water. After this, 1 μL of 
calf intestine phosphatase (CIP) was added to the reac-
tion (from NEB, Ipswich, MA) and incubated for 1 more 
hour at 37 °C. The digested and phosphatased vector was 
column purified using Qiagen PCR purification system 
(Hilden, Germany). DNA was eluted with sterile water 
and quantified using a Nanodrop spectrophotometer.
In order to obtain the FOXO3 Arm 1 for sub-cloning, 
a PCR product was prepared that had a fragment of the 
FOXO3 gene (adjacent to the CRISPR nick sites in the 
Recombinaon to disrupt FOXO3 
FOXO3
sequence 
108663463-
108663880 
FOXO3
sequence 
108663921-
108664670
Neomycin Resistance Gene 
(NPTII) 
FOXO3 gene 
disrupted 
FOXO3 Gene in 
chromosome 
FOXO3
sequence 
108663463-
108663880 
FOXO3
sequence 
108663921-
108664670
nick made by Cas9D10A and FOXO3 gRNA (HSL0001339461)   
nick made by Cas9D10A and FOXO3 gRNA (HSR0001339464)   
FOXO3
sequence 
108663463-
108663880 
FOXO3
sequence 
108663921-
108664670
Neomycin Resistance Gene 
(NPTII)FOXO3 Donor vector 
(pcDNA3-based) 
+ 
Fig. 3 Schematic of FOXO3 gene disruption with neomycin resistance cassette (NPTII). Guide RNAs were employed to nick FOXO3 gene in mamma‑
lian cell lines. The lesions were resolved by recombination with a donor vector that contained a neomycin resistance gene (NPTII) flanked by FOXO3 
sequences (that were proximal to the CRISPR Cas9‑generated nicked strands of FOXO3 in the chromosome)
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genome) with sequences on the end of each primer that 
were identical to the pCDNA3 vector next to the DraIII 
site; see Table 1 for PCR primer sequences. The FOXO3 
fragment was within 20 bases of the nick in the genome 
for recombination. This fragment was 418 base pairs in 
length, allowing a significant amount of homology to pro-
mote recombination between the donor vector and the 
nicked chromosome. The FOXO3 fragment was prepared 
using Phusion high fidelity polymerase (Thermo-Fisher, 
Waltham, MA). The FOXO3 Arm 1 PCR product was 
cleaved with DpnI for 3 h to remove plasmid DNA tem-
plate (used as template for PCR reaction); 2 μL of DpnI 
(NEB, Ipswich, MA) were added to unpurified FOXO3 
PCR product (still containing nucleotides, polymerase, 
etc.) and samples were incubated at 37  °C for 2 h. After 
DpnI digestion, the PCR product was column purified 
using Qiagen PCR purification system (Hilden, Germany) 
and eluted with sterile water. The purified PCR product 
was quantified with a Nanodrop spectrophotometer.
Gibson assembly reactions were performed using 
10 ng of vector (cut, phosphatased and column purified 
pcDNA3) with 80  ng of insert (FOXO3 fragment); the 
DNA reactants comprised a volume of 10 μL initially. To 
the DNA reactants, 10 μL of NEB Gibson assembly mix 
was added for a final volume of 20  μL (NEB, Ipswich, 
MA). These reactions were incubated at 50  °C for 1  h 
and were then transformed into chemically competent 
bacterial cells (5-alpha competent E. coli, NEB, Ipswich, 
MA) as directed by the NEB Gibson assembly kit. Trans-
formed bacterial cells were plated in dilutions (1:10, 1:100 
and 1:1000) to obtain single colonies given the high effi-
ciency of the Gibson assembly reactions. Single colonies 
were screened by restriction digest and confirmed by 
Sanger sequencing. The vector obtained from this was 
called FOXO3 Arm 1 vector.
Addition of FOXO3 Arm 2 to donor vector
The second arm for the FOXO3 donor vector was pre-
pared in a similar manner to Arm 1. The intermediate 
vector (with FOXO3 Arm 1) was cut with BstZ17I, which 
is on the other side of the neomycin resistance gene in 
the pcDNA3 plasmid compared to FOXO3 Arm 1. The 
cleaved vector was treated with CIP (1  μL CIP, NEB, 
Ipswich, MA) for 1 h and subsequently column purified. 
FOXO3 Arm 2 was amplified with the primer pair speci-
fied in Table 1, producing a product that had sequences 
on each end that were identical to the sequences proxi-
mal to the BstZ17I site in the intermediate FOXO3 Arm 
1 vector. Gibson assembly reactions were performed (as 
previously described to sub-clone Arm 1 of FOXO3) to 
obtain the final FOXO3 donor vector Figs.  2, 3. Trans-
formed bacterial cells were plated in dilutions (1:10, 1:100 
and 1:1000) to obtain single colonies given the extremely 
high efficiency of the Gibson assembly reactions. The 
complete FOXO3 donor vector was confirmed by restric-
tion fragment analysis and Sanger sequencing. The com-
plete sequence of the FOXO3 donor vector can be found 
in Additional file 1: Figure S1.
CRISPR Cas9 mutagenesis to truncate the FOXO3 
gene in mammalian cells
Transient transfections to obtain FOXO3 truncation 
mutants
Transient transfections were performed using the glio-
blastoma cell line U87MG, breast cancer cell line BT549, 
or human kidney cell line HEK 293, which were obtained 
from American Type Culture Collection (ATCC, Manas-
sas, VA) and propagated under standard conditions 
[37  °C with 5%  CO2 in media specified by ATCC sup-
plemented with 10% FBS (fetal bovine serum) and 5% 
penicillin/streptomycin (pen/strep)]. Media employed 
to grow U87MG cells was MEM, BT549 was RPMI and 
HEK 293 was DMEM. One million cells of each cell 
line was transfected using LONZA (nucleofection kit 
V, program P-20 for U87MG and BT549 and program 
X-001 for HEK 293) and were allowed to recover for 
2  days in 10  cm dishes. In each transfection, 250  ng of 
each guide RNA (gRNA) vector (Table 2) were added as 
well as 250 ng of the vector enabling Cas9D10A expres-
sion (CRISPR Cas9D10A-GFP Nickase, catalog: CAS-
9D10AGFPP, Sigma, St. Louis, MO). Guide RNA vectors 
were obtained from Sigma (St. Louis, MO) and were uti-
lized to make DNA nicks in both chromosomal FOXO3 
DNA strands (Figs.  2, 3). The FOXO3-containing por-
tions of the gRNAs are detailed in Table  2. A negative 
control gRNA (CRISPR Universal Negative Control 1, 
catalog: CRISPR06, Sigma, St. Louis MO) was utilized 
for control experiments (500 ng per transfection to have 
the same amount of DNA as mutagenesis samples). One 
microgram of FOXO3 donor vector was utilized in each 
transfection.
Table 1 PCR Primers utilized to amplify FOXO3 gene frag‑
ments for Donor Vector Gibson Assembly Reactions
a Nucleotides in bold corresponds to pcDNA3 vector sequences. Sequences in 
italics were to amplify the indicated FOXO3 arm
Primer Sequencea
FOXO3 ARM 1 F 5′‑GTGCTTTACGGCACCTCGACCCCCCGGCACAAC-
CTGTCACTGC-3′
FOXO3 ARM 1 R 5′‑CCGTCTATCAGGGCGATGGCCGCTGTAGAGCAT 
GGGCGAGAG-3′
FOXO3 ARM 2 F 5′‑CAAATAAAGCATTTTTTTCACTCGGTGGAACTG 
CCACGGCTG-3′
FOXO3 ARM 2 R 5′‑GAGTTTGGACAAACCACAACTAGGTCCAAGT 
CGCTGGGGAAC-3′
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It is important to note that the nicks directed by the 
gRNAs are staggered on the chromosome (about 40 base 
pairs apart). These gRNAs are used in concert with the 
Cas9D10A nickase (CRISPR Cas9D10A-GFP Nickase, 
catalog: CAS9D10AGFPP, Sigma, St. Louis, MO) to make 
nicks in a gene of interest [26, 28, 30–32]. It has been 
shown that Cas9D10A allows for > 100-fold increased 
specificity for genomic editing (between 200-fold and 
1500-fold based on deep sequencing experiments) [26].
For each mutagenesis, cells that survived the transfec-
tion (after 2  days of recovery) were incubated in 0.25% 
trypsin for 3  min and were placed into 10  mL of MEM 
(contained 10% FBS and 5% Pen/Strep). Ten plates of 
diluted cells (approximately 100,000 cells per 10  cm 
dish) were prepared from this mixture. G418 (0.5  mg/
mL final concentration for U87MG and BT549 and 
1.5  mg/mL G418 for HEK 293 cells) was added to each 
10  cm plate  1  day after plating. Single clones were iso-
lated from these selected dishes 4 weeks later using clon-
ing cylinders. 2–10 single colonies were obtained from 
each 10 cm plate. To clone a colony, the plate was washed 
with 2 mL 0.25% trypsin and aspirated. Cloning cylinders 
(Fisher: 0955221) were placed onto the 10 cm plate using 
sterile forceps and vaseline (to make the cylinder stick 
to the plate). 200 μL of 0.25% trypsin was added to each 
cylinder and incubated for 5 min. The 200 μL of trypsin 
was pipetted up and down ten times and then plated into 
2 mL of fresh media in a well of a six well plate.
Results
Western blot analysis with putative FOXO3 mutants
Proof-of-principle studies were done to determine muta-
tion frequencies using our described protocol in several 
mammalian cell lines: U87MG, BT549 and HEK 293. 
Figure 4 depicts the encoded FOXO3 truncation mutant 
protein. FOXO3 is an extensively characterized transcrip-
tional activator that impacts metabolism, the cell cycle, 
apoptosis and cell fate [36–38]. Disruption of the FOXO3 
gene led to the production of a truncated mutant pro-
tein that contained the first 349 amino acids of FOXO3 
(including the DNA binding domain); most of the trans-
activation domain was deleted. CRISPR Cas9 mutagen-
esis followed by selection with neomycin with U87MG 
cells allowed our group to isolate 77 putative mutants 
in one trial and 50 putative mutants in another. We con-
firmed the truncation mutants in several ways. Western 
blot analyses were performed as described previously 
[39]. Expression of FOXO3 was assessed by western 
blot analysis. Total protein was obtained from U87MG 
cells by rinsing out the 6 well plate wells with 1XPBS 
followed by directed lysis in 2× sample buffer (125 mM 
Tris–HCL at pH 6.8, 2% sodium dodecyl sulfate (SDS), 
10% 2-mercaptoethanol, 20% glycerol, 0.05% bromophe-
nol blue, 8 M urea); 2× sample buffer was added to each 
well and scraped. The lysate was collected from each well, 
placed into 1.5 mL microcentrifuge tubes and heated for 
10 min at 90 °C in a dry-bath heat block. Equal amounts 
of protein lysates were separated by sodium dodecyl sul-
fate-polyacrylamide gel (SDS-PAGE) electrophoresis at 
100  V for 1  h. The protein was then transferred onto a 
polyvinylidene fluoride (PVDF) membrane for an hour 
and 30  min then blocked in a 5% milk solution [carna-
tion powdered milk, 1× tri-buffered saline with Tween 
20 (TBST)] for an hour. The membrane was incubated 
with FOXO3 (Cell Signaling, Danvers, MA, Cat: 75D8), 
or GAPDH (Santa Cruz Biotechnology, Dallas, TX, cat: 
G-9) antibodies overnight at 4 °C then washed for 20 min 
with TBST in 5-min intervals. The blot was incubated 
with secondary antibodies. The membrane was washed 
again for 20  min in 5-min intervals and allowed to 
develop using SuperSignal West Dura Extended Duration 
Substrate luminol solution for 5 min. The BioRad Chem-
Doc XRS+ molecular imager was used to detect light 
emitted from protein—containing complexes. Western 
blot SCN files from the (BioRad ChemDoc XRS+) were 
analyzed using NIH Image J.
Western blot analysis showed that FOXO3 trunca-
tion mutant protein was much smaller than the wild-
type FOXO3, roughly 45  kDa (kilo Dalton) versus the 
full-length 80 kDa, Fig. 4. In our first attempt to isolate 
FOXO3 disruption mutants, we screened 77 putative 
clones and obtained four homozygous mutants based on 
western blot analysis, Fig. 4. Therefore, 5% of the screened 
isolates were homozygous mutant. In a repeat proof-of-
principle experiment, we found that out of 50 screened 
putative mutants, three had only the truncated form of 
FOXO3 as evidenced by the 45  kDa band (6% homozy-
gous mutation rate), Fig. 5. Three samples had both the 
truncated form of FOXO3 and the full-length FOXO3 
protein (two bands that were 45 and 80 kDa), Fig. 5. 44 
out of the 50 screened samples had full-length FOXO3 
protein (only 80 kDa band), Fig. 5. Therefore, even with 
selection, there was a low mutation rate (5–6%). This was 
not surprising given the DNA repair deficiency found in 
U87MG cells [33, 34]. We also screened for FOXO3 trun-
cation mutants in two additional cell lines: breast cancer 
BT549 and human kidney HEK 293. Out of 56 screened 
isolates in BT549 cells, five were homozygous mutant 
(approximately 9%), Table 3. We found that only one of 
Table 2 Guide RNA sequences
Gene I.D. for construct Sequence
FOXO3 HSL0001339461 CTTACTGAAGGTGACAGGCTGG
FOXO3 HSR0001339464 CACGGCTGACTGATATGGCAGG
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77 putative mutants screened in HEK 293 background 
was homozygous for FOXO3 truncation, Table 3. There-
fore the mutant frequency was between 1.3 and 9% in the 
tested cell lines.
In our experiments, we were able to screen for a change 
in protein size. Other applications of this protocol could 
use similar screening techniques when the mutation 
frequency is low. Attachment of a GFP fusion to a gene 
of interest could be screened by western blot analysis, 
microscopy or flow cytometric analysis. Alternatively, 
genes could be deleted, leading to a loss of a protein of 
interest in western blot analysis. The ability to select 
mutants with neomycin and then screen using western 
blot analysis (or other technique) greatly facilitates the 
isolation of mutants.
Genotyping CRISPR Cas9 mutants
All putative homozygous FOXO3 disruption mutants 
that were identified by western blot analyses (Figs.  4, 
5, and Table  3) were further confirmed using PCR and 
were later confirmed by Sanger sequencing. DNA was 
isolated from 1 million cells from each clone. The cells 
were removed from plates using trypsin and centrifuged 
at 700×g for 5  min. Cells were re-suspended in 500  μL 
of Buffer (10 mM Tris 7.4, 10 mM NaCl, 25 mM EDTA, 
1% SDS). 25 μL of Proteinase K (50 U/mL stock, catalog: 
03115828001, Roche, Mannheim, Germany) was added 
to each sample followed by an 18 h incubation at 37 °C. 
Next, the sample was extracted with an equal volume of 
phenol, followed by centrifugation at top speed in phase 
lock tubes (Quanta Biosciences, Beverley, MA, catalog: 
2302820). DNA was precipitated from the supernatant 
by adding 3 μL of 20 mg/mL glycogen, 50 μL of sodium 
acetate and 1 mL of 100% ethanol (stored at − 80 °C over-
night followed by 20 min of centrifugation at 17,000×g). 
The DNA pellets were washed with 70% ethanol, dried 
and re-suspended in sterile water. PCR was performed 
to identify clones that had NPTII integration into the 
FOXO3 locus using the primers in Table 4. The forward 
primer for PCR was approximately sixty bases upstream 
of the FOXO3 fragment found in Arm 1 of the FOXO3 
donor vector. Therefore, the primer sequences employed 
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antibodies are indicated. Wild‑type FOXO3 was approximately 80 kDa, whereas, mutant FOXO3 protein was approximately 45 kDa. Out of 77 puta‑
tive mutants screened, only four were homozygous mutant (confirmed by Sanger sequencing)
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for mutant detection by PCR were absent from the donor 
vector and were only found in chromosomal FOXO3. The 
reverse primer was part of the NPTII cassette used to dis-
rupt FOXO3. Most of the negative samples were positive 
for intact vector integration (data not shown). The PCR 
products (employed for detecting FOXO3 disruption) 
were column purified using Qiagen PCR purification sys-
tem (Hilden, Germany) and eluted with sterile water. The 
purified PCR product was quantified with a Nanodrop 
spectrophotometer. Purified PCR products were ana-
lyzed by Sanger sequencing; a primer containing FOXO3 
chromosomal sequences (that were not present in the 
donor vector) was utilized, Table  4. Sanger sequencing 
confirmed that the homozygous FOXO3 mutants iden-
tified by western blot analyses had the designed gene 
disruptions.
Discussion
CRISPR Cas9 technology is an emergent genome editing 
tool. Here, we describe a protocol to disrupt the FOXO3 
gene in mammalian cells using a neomycin cassette. To 
decrease off-target effects, we employed 2 guide RNAs, 
a mutant Cas9D10A nickase and a FOXO3 donor vec-
tor that was constructed by Gibson assembly (to enable 
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mutant FOXO3 protein was approximately 45 kDa. This second proof of principle screen examined 50 potential FOXO3 mutant clones. Three of 
these were homozygous mutant (16, 25 and 43), three appeared to be heterozygous (14, 30 and 31) and 44 were wild‑type. The homozygous 
mutants were confirmed by Sanger sequencing
Table 3 CRISPR Cas9 mutation frequencies in mammalian 
cell lines
a These mutants are shown in western blot analyses found in Figs. 4, 5
Cell line G418-resistant 
isolates screened 
by western blot 
analysis
Number 
of homozygous 
truncation 
mutants
Homozygous 
mutation  
frequency 
(%)
U87MG Trial 1 77 4a 5
U87MG Trial 2 50 3a 6
BT549 56 5 9
HEK293 77 1 1.3
Table 4 Primers utilized to detect and sequence FOXO3 
gene disruption
Primer name Sequence
FOXO3 F (for detection of disruption) 5′‑GTGCTTCAGGATCGCTTCA‑3′
Neo cassette R (for detection of 
disruption)
5′‑TGCATGCTTTGCATACTTCTG‑3′
FOXO3 seq. (for sequencing disruption 
mutants)
5′‑CTCGGTTTTGGACCATTCTG‑3′
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the selection of mutants with G418). Selected mutants 
were validated by PCR, Sanger sequencing and western 
blot analysis. This protocol could be adapted to readily 
disrupt or modify genes of interest in order to alter the 
genetic background of mammalian cell lines in a directed 
manner. The ability to select for the disruption of genes 
using neomycin resistance accelerates mutant isolation, 
especially when mutation frequencies are low or when 
mutations are deleterious to cells.
Many cancer cell lines including U87MGs have defi-
cient DNA repair [33, 34]. Homozygous mutation fre-
quencies varied depending on the cell line as seen in 
Table  3. We found that even with selection, 5–6% of 
screened putative mutants were homozygous for FOXO3 
disruption in U87MG cells (Figs.  4, 5, Table  3). BT549 
breast cancer cells had the highest efficiency of 9%. 
HEK 293 cells had the lowest homozygous mutation 
frequency of only 1.3% (Table  3), whereas many hete-
rozygous mutants were obtained for this cell line (8 out 
of 77 screened by western blot, data not shown). Simi-
lar homology directed repair (HDR) frequencies were 
observed in HEK 293 backgrounds (0.2–1.5%) with the 
Cas9 D10A nickase in previous studies [24, 40, 41]. HDR 
frequencies using CRISPR Cas9 vary depending on the 
cell line, enzymes utilized (Cas9 D10A versus wild-type 
Cas9), transfection protocols employed, specific guide 
RNAs employed (including PAM sequence variances) 
and the specific locus being mutated [23, 27, 29, 40]. It 
was surprising that U87MG and BT549 cell lines had 
higher gene disruption frequencies than HEK 293 cells. 
Perhaps NHEJ more efficiently resolved the Cas9-derived 
nicks in HEK 293 cells, leading to lower homology 
directed repair in this setting. NHEJ frequencies were 
found to be higher than HDR frequencies in 293 back-
grounds (50–60% compared to 1%, respectively) [40]. In 
addition, BT549 and U87MG cells harbor null mutations 
in the tumor suppressor PTEN, which impacts DNA 
repair via numerous mechanisms in a context-dependent 
manner [33, 43–46]. Loss of PTEN hinders DNA repair, 
which may shift double strand break resolution to favor 
HDR over NHEJ in U87MG and BT549 cell lines [33].
Conclusions
We describe a CRISPR Cas9 genome editing protocol 
for mammalian cell lines by constructing and employing 
a custom donor vector that contains a neomycin resist-
ance cassette. We provide a detailed, step-by-step proto-
col for donor vector design and construction using the 
pcDNA3 vector [47]. Custom donor vectors can be dif-
ficult to clone and expensive to purchase. We provide a 
simple, efficient protocol to obtain custom donor vectors 
from the common pcDNA3 mammalian expression vec-
tor. We also provide step-by-step instructions on how to 
select mutants and isolate clones. This protocol will allow 
researchers to overcome the barrier of low mutation effi-
ciency commonly found in mammalian cell lines. Impor-
tantly, researchers can employ this protocol to build 
custom donor vectors in order to study novel gene func-
tions and/or examine the localization of tagged proteins 
using endogenous expression levels.
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